News | July 13, 2011

Akron Children's Hospital to Demonstrate Heart Ablation Procedure via Live Webcast

July 13, 2011 – Many children and teens suffering from tachycardia, or rapid heart rate, have relied on medication to regulate their heart rhythms and control symptoms such as fatigue, dizziness and fainting spells. However, doctors at the Akron Children's Hospital Arrhythmia Center have made great strides in curing tachycardia with minimally invasive procedures.

Their skills will be on display during a one-hour webcast that will be available beginning Thursday, July 14, at 6 p.m. (Eastern). The webcast will include footage from a cryoablation procedure, as well as interviews with Arrhythmia Center director John Clark, M.D., associate director Grace Smith, M.D., and the patient and family.

During the cryoablation procedure, electrode catheters – long, slender, flexible wires – are threaded into the heart to map or locate the precise area of the heart causing the irregular rhythm. Once identified, the surgeon destroys the abnormal heart tissue by freezing it off with nitrous oxide. In other cases, radiofrequency ablation is used to burn the affected area.

Clark and Smith recommend cryoablations as the primary therapy for children age 5 and older with rapid heart rates. Approved by the U.S. Food and Drugs Administration (FDA) in 2003, Akron Children's was the first pediatric hospital in Ohio to offer cryoablation, which cures 90 to 95 percent of patients.

Clark and Smith perform most cardiac ablations without radiation, an advancement significant to young patients at risk of lifelong cumulative radiation exposure through regular diagnostic procedures.

For more information: www.akronchildrens.org

Related Content

CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
FDA Approves TactiCath Contact Force Ablation Catheter, Sensor Enabled
Technology | Ablation Systems | January 21, 2019
Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force Ablation Catheter,...
First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
FDA Approves Biosense Webster's Tag-Index Guided Ablation Software
Technology | Ablation Systems | October 09, 2018
Biosense Webster Inc. recently received approval from the U.S. Food and Drug Administration (FDA) for its Visitag...
Medtronic Cryoballoon Improves Quality of Life, Reduces Systems of Persistent Atrial Fibrillation
News | Ablation Systems | August 28, 2018
Medtronic plc announced new findings from the CRYO4PERSISTENT AF clinical trial demonstrating improved quality of life...
Thermedical Announces FDA IDE Approval for Clinical Study of Durablate Catheter
News | Ablation Systems | August 02, 2018
Thermedical announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device...
Boston Scientific to Acquire Cryterion Medical Inc.
News | Ablation Systems | July 13, 2018
Boston Scientific Corp. recently announced a definitive agreement to acquire Cryterion Medical Inc., a privately-held...
Treating AFib With Ablation Reduces Mortality and Stroke
News | Ablation Systems | July 05, 2018
Using catheter-based ablation instead of medications alone reduces the risks of death and stroke in patients with the...
LuxCath Showcases OmniView Light-Guided Ablation Catheter at HRS 2018
News | Ablation Systems | May 22, 2018
LuxCath LLC showcased the next generation of its proprietary OmniView light-guided catheter ablation system at the 2018...
Overlay Init